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Abstract
Objective: Sudden unexpected death in epilepsy (SUDEP) is associated to the high
premature mortality observed amongst people with epilepsy. It is, however, considered
a rare event in China, probably due to lack of awareness and limitation of studies in
the country. We aimed to provide some initial estimation of the burden of SUDEP in
China.
Methods: We established a large Chinese community-based cohort of people with
epilepsy between January 2010 and December 2011. For any participant who died
during follow up, detailed information on cause of death was obtained using a
specifically designed Verbal Autopsy Questionnaire. All cases were reviewed by a
multidisciplinary expert panel and re-investigated if necessary. SUDEP incidence rates
were estimated and case details provided.
Results: The cohort consisted of 1,562 people with epilepsy and during a median 5
years follow-up, 72 deaths were reported. The all-causes death incidence was
11.23(95%CI 8.86-14.07) per 1,000 person-years. Fifteen of the deceased died
suddenly and unexpectedly in a reasonable state of health in the week preceding death.
We recorded detailed information of these 15 deaths. Thirteen were considered to be
probable SUDEP and two possible SUDEP. The incidence of probable SUDEP was
2.03(95%CI 1.13-3.38) per 1,000 person-years and the incidence of all suspected
(probable and possible) SUDEP was 2.34(95%CI 1.36-3.77) per 1,000 person-years.
Significance: The incidence of SUDEP was relatively high among Chinese people
with epilepsy when compared with previous community-based studies from
high-income countries. The burden of SUDEP in China requires assessments.
Key words: Premature mortality, SUDEP, Verbal Autopsy, Seizure
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1.Introduction
Sudden unexpected death in epilepsy (SUDEP) is associated to the premature
mortality seen amongst people with epilepsy. In western countries, the incidence of
SUDEP varies with the sample population, increasing from 0.35 to 2.3 in community
samples to 1.1 to 5.9 in epilepsy clinics and between 6.3and 9.3 in participants of
epilepsy surgery programs [1]. One long term study reported that in a cohort of people
with epilepsy followed for over 30 years, SUDEP accounted for 30% of all death [2].
There have been some Chinese case reports of SUDEP with autopsy but overall
studies of SUDEP are still limited in China where there are over 9 million people with
epilepsy [3].Only two prospective mortality studies have been reported from China [4-5];
and they did not estimate SUDEP incidence making comparisons with reports from
other countries difficult. The large variation in the proportional mortality ratios for
SUDEP (14.7% [4] and 1% [5]) between these two studies suggests some
methodological shortcomings in the diagnosis of SUDEP. Autopsies are rarely
acceptable in Asia and particularly in China and this compound the issue.
We carried out a study to estimate the incidence of SUDEP in a Chinese
population using specifically designed instruments to overcome some of the shortages
and to report detailed information about cases identified.
2. Material and Methods
2.1 Study cohort with epilepsy
Between January 2010 and December 2011, people with epilepsy were recruited
from rural areas in the Chinese provinces of Henan, Shanxi, and Ningxia,, as a part of
the “Validation of Clinical Assessment Tools for Population Genetic Studies of
Epilepsy (1R21NS069223-01, NIH/NINSD)”. People with epilepsy aged 2-80 years
5 Ge
were eligible for inclusion, they were, however, excluded if: 1) they had non-epileptic
attack disorder; 2) their seizure were related to alcohol or drug abuse; 3) their seizures
resulted from progressive neurological or systemic disorders; 4) their adherence to
their drug regime or seizure control couldn’t be adequately assessed; 5) they were
pregnant; 6) they or their guardians were unable to provide consent.
2.2 Clinical assessment and data collection at baseline
The baseline clinical assessment procedure was in two stages. In stage 1, trained
village physicians used door-to-door interviews to identify individuals who were
having seizures, who had at least one family member who had witnessed seizures and
was familiar with their medical history. They recorded demographic details, clinical
symptoms, birth and developmental history, family history, medical history, treatment
history. In stage 2, each person identified in stage 1 as having epilepsy went to the
designated provincial epilepsy center and were reviewed by a neurologist and had the
diagnosis confirmed or refuted. At this stage the neurologist also completed a full
diagnostic questionnaire covering 1) demographics; 2) age of onset and seizure
frequency; 3) full antiepileptic treatment history; 4) risk factors, such as history of
CNS infections, brain injury, family history of epilepsy (in close relatives), abnormal
birth history, stroke, and brain tumor; 5) seizure-associated medical history: history of
status epilepticus and febrile seizures; 6) results of EEG and MRI/CT. We classified
seizures as generalized, focal or unknown according to ILAE guidelines [6]. The
putative etiology of epilepsy was classified as genetic, structural/metabolic or
unknown. A panel of epilepsy-experienced neurologists (PK, JWS, and ZH) reviewed
diagnoses, and any discrepancies were resolved by consensus.
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2.3 Follow-up procedure
Two follow-up visits were conducted during March 2013 to October 2014, and
October 2015 to March 2016. The local physician interviewed each participant at their
home. The interview was conducted via mobile phone or by interviewing family
members for those who were offsite. The interview covered current clinical,
treatments and survival status. Loss-to-follow-up was defined as those whose survival
status could not be established during either follow-up.
2.4 Verbal Autopsy Questionnaire
For those who had died, death certificates were collected from the appropriate
office. A specifically designed Verbal Autopsy Questionnaire (VAQ) was used (see
supplement 1). Primary-care physicians asked relatives or local physicians for specific
death-related questions as required by the VAQ including place and timing of death,
body position when found, whether death was witnessed, whether a seizure preceded
death or whether there was circumstantial evidence for a seizure before death
(incontinence, bitten tongue),whether there was evidence or suspicion for suicide,
whether there were injuries and whether the victim was in a reasonable state of health
in the week prior to demise. A detailed description of death and the putative cause
were also recorded.
2.5 Confirmation of death causes and SUDEP
All the VAQs were reviewed by an expert panel consisting of neurologists (YG,
JWS), neuro-epidemiologist (DD) and forensic pathologists (BXL and JW). Inquiries
were made in case of uncertainties or unclear records. YG visited study sites to collect
further data to clarify doubts until the panel had sufficient information to attribute a
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putative cause of death for each case. These were attributed by consensus after
consideration of all available information according to the International Classification
of Diseases, 10th Edition (ICD-10) [7]. The "unknown" cause of death included those
without any information. SUDEP was defined as sudden unexpected death in an
individual with epilepsy with or without evidence of a seizure, and excluding
documented status epilepticus, where postmortem examination does not reveal an
anatomic or toxicological cause of death [8], and classified [9] as definite SUDEP,
probable SUDEP (meets all criteria, but lacks postmortem data). The criteria for
probable SUDEPwere:1) the victim had epilepsy; 2) the victim died unexpectedly
while in a reasonable state of health; 3) the death occurred ‘‘suddenly’’ (in minutes),
when known; 4) the death occurred during normal activities (e.g. in or around bed, at
home, at work) and benign circumstances; 5) an obvious medical cause of death was
not found. Criteria for possible SUDEP were: SUDEP cannot be ruled out, but there is
insufficient evidence regarding the circumstances of the death and no postmortem
report is available. Full postmortem and toxicological data are not available in rural
China, so we attributed probable SUDEP where the victim died suddenly and
unexpectedly while in a reasonable state of health in the week prior to death and
where there was no other plausible cause of death and foul play was ruled out.
2.6 Standard protocol approvals, registrations, and patient consents
The original study was approved by the joint Chinese University of Hong
Kong-New Territories East Cluster Research Ethics Committee and the institutional
review board of the Beijing Neurosurgical Institute in China. The follow-up exercise
was approved by the Medical Ethics Committee of Fudan University affiliated
Huashan Hospital, Shanghai, China. Written informed consent was obtained from all
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participants and/or their legally acceptable guardians.
2.7 Statistical analysis
Continuous variables are expressed as mean (SD), or median (minimum,
maximum), and categorical variables as counts and frequencies (%).Student t-test was
used to compare continuous variables. Chi-square test or Kruskal-Wallis test was used
for comparing categorical variables.
Incidence rates of all-cause mortality and SUDEP cases were estimated as the
number of incident cases occurring during the follow-up period divided by the
cumulative follow-up period of all subjects, described as “per 1000 person-years”,
and results presented with 95% confidence intervals (CIs).Cox proportional hazards
regression model was used to estimate the relative risk (RR) with 95% CIs of
all-cause mortality and SUDEP, within the different subgroups of gender, age of
onset, age at the baseline, seizure type, treatment, and remission. Individuals were
censored if they were lost to follow-up.
All p-values and 95%CI were estimated in a two-tailed fashion. Differences were
considered to be statistically significant at p<0.05. Data were analyzed using SPSS
16.0 (SPSS Inc., IL, USA).
3. Results
3.1 Characteristics of subjects at the baseline and follow-up
A total of 1,562 people were enrolled (baseline clinical and demographic
characteristics provided in Table 1. Sixty percent were on anti-epileptic drug (AED)
monotherapy and only 20% were in one-year remission when enrolled. A study
flowchart is provided in Fig 1. We were unable to determine survival status of 105
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people in both two follow-ups thus the lost-to-follow up rate was 6.7%. No significant
differences were found for baseline characteristics between those who were followed
and those lost to follow-up (Table 1).
We also compared the baseline characteristics between survivors and those who
died. People who died were older (median age: 47.5 years and age of onset: 20 years)
than those who survived and more likely to be males (72.2%) and this was significant
(p=0.014). The proportion of those who were in one-year remission at baseline was
significantly lower in those who died than in those who survived (11.1% vs. 20.7%,
p=0.045).
3.2 Mortality outcome during the follow-up
We identified 72 deaths during a median of 57 months of follow-up. The
incidence of all-cause death was 11.23(95%CI 8.86-14.07) per 1,000 person-years
(table 2). The median age at deaths was 47.5(11-90) years. The incidence of all-cause
death in different subgroups are given in Table 2. The risk of death among men was
86% [RR 1.86 (95% CI 1.11-3.12)] higher than in women. The mortality risk
increased with age and age of onset. The RR was 1.22 (95% CI 0.49-3.05) for those
whose age was 18 to 60 years old, and was 4.31(95% CI 1.60-11.62) for those whose
age was over 60 years old (both compared with those aged less than 18 years). The
RR was 1.70 (95% CI 1.05-2.75) for those with age of onset was 18 to 60 years old,
and RR was 5.24 (95% CI 1.85-14.82) for those with age of onset over 60 years old,
compared with those whose onset was at less than 18 years. Individuals who had
frequent seizures had a higher risk of death ([RR 2.40(95% CI 1.09-5.27)] in those
who had 1 to 4 seizures per month, and [RR 2.41(95% CI 1.03-5.64)] in those who
had over 4 seizures per month, compared with those who were in one year remission
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at baseline).
As shown in Figure 1, the most common cause of death was accidental (30.6%)
(8 drowning, 4 traffic accident, 4 poisoning, 3 falling and 3 other accidents). Fifteen
deaths (20.8%) were sudden and unexpected. and were classified as suspected SUDEP
cases.
3.3 Characteristics of SUDEP cases
Detailed information of the suspected SUDEP cases is provided in Table 3. Most
(10/15) were male. All had convulsions either focal seizures with secondary
generalization (8/15) or generalized tonic-clonic seizures (7/15). Age of death ranged
from 20-90 years and 10/15 died before the age of 60. Five deaths were witnessed,
and a seizure before death was reported in four (3 had confirmed and 1 had a
suspected seizure). Thirteen of the 15 died in the bedroom. Only two were found dead
in a prone position. Seizure numbers in the year before death was available in 14/15
and none of them had been seizure free.
We regarded 13 of these suspected SUDEP cases as probable SUDEP and 2 as
possible SUDEP (they were 80 and 90 years old and without sufficient evidence of a
preceding seizure).
3.4 Incidence of SUDEP
The incidence of probable SUDEP was 2.03(95%CI 1.13-3.38) per 1,000
person-years, and the incidence of probable and possible SUDEP was 2.34(95%CI
1.36-3.77) per 1,000 person-years. We report SUDEP incidence in different subgroups
in Table 2. SUDEP incidence and RRs were explored in males, age and onset age over
60 years old, genetic/unknown etiology, focal with secondary generalized seizure type,
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non AED treatment, and more seizure frequency, but none was found to be
statistically significant.
4. Discussion
In this large prospective community-based Chinese study, we identified cases of
SUDEP and estimated a relatively high incidence for SUDEP. Studies from
high-income countries suggest that SUDEP is responsible for up to 30% [2, 10-12] of
deaths and its leading cause of epilepsy-related death [2]. There is little data concerning
SUDEP in China as only two studies have reported the proportional mortality ratios of
SUDEP in epidemiological studies. A study from West China reported15 probable
SUDEP cases (14.7%) during a 2-year follow-up period [4]. A further study identified
only two probable SUDEP cases (1%) during the over 6-year follow-up period [5]. In
the current study, we found 18% of the deceased were possible SUDEP during a
5-year follow-up period. The variance between these studies suggests difficulties in
diagnosing SUDEP accurately in resource-poor settings, especially where
post-mortem examination are rare and usually unacceptable in traditional cultures
such as in China.
In the current study, we attempted to improve SUDEP diagnosis through several
methods. Firstly, we designed the VAQ based on widely-used SUDEP criteria [9].
Secondly, we did not accept the putative cause of death as in the death certificate.
SUDEP might be easily misdiagnosed as heart attack, stroke or other causes of sudden
death by unfamiliar reporters. Our expert panel, who were all familiar with SUDEP,
reviewed all the VAQs, paying particular attention to those in whom the reported or
certified cause of death was cardiac, cerebral vascular, unknown or sudden. If data
was not sufficient to support the reported cause of death, further inquiries were made.
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Thirdly, we established a multi-disciplinary panel to attribute causes including two
experienced forensic pathologists and their input helped to establish more accurate
putative causes. Fourthly, we report detailed information of all suspected SUDEP
cases to provide an overall impression of the cases in our study.
We identified 15 sudden, unexpected deaths, and 13 of these cases were regarded
as probable SUDEP and 2 as possible. These 13 probable cases meet the criteria
without autopsy. Two cases were classified to possible SUDEP as they were older
(>79years), which increases the risk for other causes of sudden death (cardiac attack,
pulmonary embolus). In most previous studies, the age of SUDEP cases were mainly
younger than 60 years [2, 12-20], and the incidence in the elderly was relatively low.
SUDEP might, however, be under-diagnosed in older people in whom sudden death
might be attributed to other causes without careful investigation of alternatives [1].
Many previous studies might also not have been able to investigate SUDEP in elderly
people as often these studies focus on childhood-onset epilepsy and most participants
not old enough. In our study, 144 participant were older than 60 years and SUDEP
incidence was [7.48(95%CI 2.38-18.04)] much higher than in those younger than
60([2.10(95%CI 1.11-3.66)]. Due to longer life-expectancy, the proportion of elderly
may increase further and this may also be reflected in future SUDEP studies.
The incidence of all suspected (probable and possible) SUDEP was 2.34(95%CI
1.36-3.77) per 1,000 person-years, which is out of the range of the incidence (0.35-2.1
per 1,000 person-years) from community-based studies from high-income countries
(Table 4).This may be the result of the population studied and definitions used (we
included probable and possible cases in the incidence estimation; in most studies, only
definite and probable cases are included). When focused on the incidence of probable
SUDEP, the incidence in the current study (2.03(95%CI 1.13-3.38) per 1,000
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person-years) falls in the range of previous reports (0.35-2.1 per 1,000 person-years)
(Table 4).
Prone position was found in 42%-81% of SUDEP cases in previous reports in
western population[21]. However, we found only 2 (13%) of SUDEP cases in prone
position in our study. Larger-sampled studies are needed to clarify the association
between prone position and SUDEP in Chinese people with epilepsy.
Baseline characters of the participants in our study were comparable to the
previous multi-centered cohort in mainland China[5]. There was no evidence for major
selection bias in the current study.
Post-mortem examinations are rare in mainland China, especially in rural areas
and this poses difficulties in investigating SUDEP. Without an autopsy, we were not
able to confirm definite SUDEP cases and causes could only be putative. This is a
major limitation. Our purpose, however, was to investigate the presence of SUDEP in
China and to provide an initial incidence estimation as accurately as possible, within a
known background of a lack of autopsies. In a UK study 40% of subjects who died
suddenly and might otherwise have had a diagnosis of SUDEP, were shown at
post-mortem to have probable cardiovascular causes of death [10].So we might have
overestimated SUDEP incidence.
5.Conclusion
There are over nine million people with epilepsy in China. Our results suggest
that yearly SUDEP may kill over 20,000 people. Further prospective Chinese studies
with larger sample size and longer follow-up periods are urgently needed to examine
risk and protective factors in order to seek proper interventions to reduce the burden
of SUDEP.
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Table 1 Demographics and clinical characteristics of people with epilepsy in the original cohort, those lost-to-follow up, and those followed up
All people with
epilepsy in the
initial cohort
Lost to follow-up*
Followed up
p-value
Alive Deceased
Baseline characteristics n=1,562 n=105 n=1,385 n=72
Age, year, median(range) 38 (2-88) 38 (4-78) 38(2-83) 47.5 (10-88) 0.001
Age of onset, year, median(range) 14 (<1-78) 13 (<1-63) 14(<1-77) 20 (1-78) 0.014
Gender
Male, n (%) 904 (57.9) 54(54.1%) 798(57.6) 52 (72.2) 0.014
Female, n (%) 658 (42.1) 51(48.6%) 587(42.4) 20 (27.8)
Etiology
Genetic/Unknown, n (%) 1,137 (72.8) 72(68.6%) 1016(73.4) 48 (66.7) 0.212
Structural/Metabolic, n (%) 425 (27.2) 33(31.4%) 369(26.6) 24 (33.3)
Seizure type
Focal without secondary
generalized, n (%) 103(6.6) 9(8.6) 89(6.4) 5(6.9%)
Focal with secondary
generalized, n (%) 776(49.7) 61(58.1) 677(48.9) 38(52.8) 0.829
Generalized, n (%) 675 (43.2) 35(33.3) 611(44.1) 29 (40.3)
Unknown 8(0.5) 0(0) 8(0.6) 0(0)
AED treatment
None 245(15.7) 16(15.4) 219(15.8) 10(14.1)
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Monotherapy 923(59.2) 57(54.8) 823(59.5) 43(60.6) 0.926
Polytherapy 391(25.1) 31(29.8) 342(24.7) 18(25.4)
Seizure frequency within one year
before baseline
Terminal one year remission, n (%) 310 (20.2) 21(21.0) 281(20.7) 8(11.1)
<1/month 520(34.0) 30(30.0) 470(34.6) 20(27.8) 0.045
1-4/month 447(29.2) 32(32.0) 387(28.5) 28(38.9)
>4/month 254(16.6) 17(17.0) 221(16.3) 16(22.2)
* No significant differences were found for baseline characteristics between those who were followed and those lost to follow-up
AED: Anti-epileptic drug
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Table 2 Incidence of all-cause death and SUDEP in different subgroup
All-cause mortality Probable SUDEP
Probable and
possible SUDEP
Person-yrs
of
follow-up
incidence /1,000
person-years (95%
CI)
RR (95%CI)
incidence /1,000
person-years (95%
CI)
RR (95%CI)
incidence /1,000
person-years (95%
CI)
RR (95%CI)
Total 6409 11.23(8.86-14.07) 2.03(1.13-3.38) 2.34(1.36-3.77)
Gender
Female 2676 7.47(4.69-11.34) 1 1.12(0.29-3.05) 1 1.49(0.47-3.61) 1
Male 3733 13.93(10.51-18.13) 1.86(1.11-3.12) 2.68(1.36-4.78) 2.39(0.66-8.68) 2.95(1.55-5.12) 1.97(0.63-6.19)
Onset age
<18 3833 8.35(5.35-11.65) 1 1.83(0.80-3.61) 1 1.83(0.80-3.61) 1
18-60 2463 14.22(10.06-19.55) 1.70(1.05-2.75) 2.44(0.99-5.07) 1.35(0.45-4.01) 2.84(1.24-5.62) 1.56(0.55-4.47)
>60 90 44.44(14.12-107.20) 5.24(1.85-14.82) NA 11.10(0.56-54.80) 6.46(0.79-52.57)
Age at baseline
<18 648 7.72(2.83-17.10) 1 NA NA
18-60 5226 9.38(7.01-12.29) 1.22(0.49-3.05) 2.10(1.11-3.66) 1 2.10(1.11-3.66) 1
>60 535 34.35(21.00-53.24) 4.31(1.60-11.62) 3.74(0.63-12.35) 1.78(0.27-7.14) 7.48(2.38-18.04) 3.55(0.98-10.81)
Etiology
Structural/Metabolic 1708 14.05(9.21-20.59) 1 1.17(0.20-3.87) 1 1.76(0.45-4.78) 1
Genetic/Unknown 4701 10.21(7.61-13.42) 0.73(0.45-1.19) 2.34(1.23-4.07) 1.98(0.44-8.93) 2.55(1.38-4.34) 1.44(0.41-5.11)
Seizure type
Focal without 420 11.91(4.36-26.40) 1 NA NA
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secondary
generalized
Generalized 2814 9.95(6.74-14.18) 0.87(0.34-2.34) 2.13(0.86-4.42) 1 2.13(0.86-4.42) 1
Focal with secondary
generalized
3137 12.29(8.86-16.63) 1.01(0.40-2.57) 2.21(0.96-4.36) 1.04(0.34-3.28) 2.84(1.38-5.20) 1.33(0.47-4.02)
AED treatment
None 973 10.29(5.23-18.34) 1 3.09(0.79-8.40) 1 4.12(1.31-9.93) 1
Monotherapy 3844 11.19(8.20-14.93) 1.10(0.55-2.20) 2.08(0.97-3.95) 0.66(0.18-2.49) 2.34(1.14-4.30) 0.56(0.17-1.82)
Polytherapy 1585 11.36(6.94-17.60) 1.11(0.51-2.41) 0.63(0.03-3.11) 0.20(0.02-1.93) 0.63(0.03-3.11) 0.15(0.02-1.35)
Seizure frequency
within one year before
baseline
Terminal one year
remission at baseline
1254 6.38(2.96-12.11) 1 0.80(0.04-3.93) 1 0.80(0.04-3.93) 1
<1/month 2162 9.25(5.81-14.03) 1.46(0.64-3.31) 0.93(0.16-3.06) 1.15(0.10-12.65) 1.38(0.35-3.78) 1.72(0.18-16.58)
1-4/month 1842 15.20(10.30-21.68) 2.40(1.09-5.27) 2.71(0.99-6.02) 3.34(0.39-28.63) 3.26(1.32-6.78) 4.029(0.49-33.48)
>4/month 1039 15.40(9.12-24.47) 2.41(1.03-5.64) 4.81(1.76-10.67) 5.94(0.69-50.86) 4.81(1.76-10.67) 5.955(0.70-50.97)
SUDEP: Sudden unexpected death in epilepsy; AED: Anti-epileptic drug; NA: not available; RR: relative risk; CI: confidence interval
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Table 3 Detailed information of suspected SUDEP cases
Pt.
NO.
SUDEP
classification
Reported
cause of
death
Gender Seizure type
number of
seizures within
the year before
death
age at
onset
(years)
age at
death
(years)
Place Position
Seizure
before
death
Time of Death or
Found Death
Witnessed Description
1 probable unknown male generalized 24 15 20 bedroom latericumbent suspected 10 a.m. no
found dead at 10 a.m. with
foaming at the mouth
2 probable unknown female generalized 10 14 22
living
room
latericumbent no 11 a.m. yes
Sudden loss of consciousness at
11 a.m., death confirmed at
doctor's arrival
3 probable seizure male
focal with
secondary
generalized
unknown 4 23 bedroom unknown confirmed 1 a.m. yes
seizure during sleep, found dead
at 1 a.m.
4 probable unknown male generalized 8 5 27 bedroom latericumbent unknown unknown no found dead at morning
5 probable seizure female
focal with
secondary
generalized
11 3 28 bedroom prone confirmed unknown yes sudden death during a seizure
6 probable unknown male generalized 4 21 35 bedroom supine unknown 10 a.m. no
Living with his family, found
dead at 10 a.m.
7 probable asphyxia female
focal with
secondary
generalized
4 3 39 bedroom supine suspected 3 a.m. no
Living with family, found dead
at 3 a.m. with incontinence
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8 probable
coronary
heart disease
female generalized 3 22 42 bedroom prone unknown 9 a.m. no
Work overnight till 8 a.m.,
found dead at 9 a.m. by her
colleague.
9 probable unknown male generalized 13 17 46 bedroom supine suspected 8 a.m. no
Living with his family, found
dead at 8 a.m. with incontinence
and damaged surroundings
10 probable unknown male
focal with
secondary
generalized
2 32 55 bedroom supine unknown 7 a.m. no
living in the nursing home,
found dead at 7 a.m.
11 probable unknown male
focal with
secondary
generalized
5 22 62 bedroom latericumbent confirmed night yes
sudden death during a seizure at
night
12 probable
cerebral
hemorrhage
male
focal with
secondary
generalized
4 53 67 bedroom latericumbent suspected 10 p.m. no
Sudden fall down with loss of
consciousness during walking at
6 p.m., and sent home. No
abnormal symptom or sign
found after wake up by doctor.
Sudden death at 10 p.m.
13 probable unknown male generalized 3 37 67 outside supine no 4 p.m. yes
sudden fall down on his way to
work, cardiopulmonary
resuscitation failed
14 possible unknown male
focal with
secondary
generalized
10 50 80 bedroom supine unknown 8 a.m. no
Living with family, found dead
at 8 a.m.
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15 possible
coronary
heart disease
female
focal with
secondary
generalized
3 78 90 bedroom supine no 6 a.m. no
Living with family, asked her
son to give her water to drink at
2 a.m., found dead at 6 a.m.
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Table 4 Summary of incidence of SUDEP from previous community-based studies
Reference
Definition of
SUDEPa
Study site Study design
Median/average
years followed
Sample
size
Age range of
study
population at
baseline(years)
Age range
of SUDEP
cases(years)
Number of
SUDEP cases
SUDEP incidence (per
1,000 person-years)
The current study Annegers China prospective 4.4 1,562 2-88 20-90
15(13 probable,
2 possible)
2.34
Sillanpää, et al. [2]
(2010)
Annegers Finland prospective 40 245 onset age<16 4-49
18(15 with
autopsy)
2.1
Langan [14]
(1998)
Other Ireland retrospective 3 3,400 All ages 14-59
15(all with
autopsy)
1.5
Tennis,et al. [22]
(1995)
Other Canada retrospective 7.83 3,688 15-49 NG
39(18 definite or
probable, 21
possible)
1.4
Grønborg [17]
(2014）
Nashef Denmark retrospective 9 1,974 <18 8-24
9(5 with
autopsy)
0.8
27 Ge
Holst [20]
(2013)
The definition of
Nashef and the
classification of
the Annegers'
Denmark
historical
cohort
3.7 33,022 1-35 17.3–29.4
50(26 with
autopsy)
0.41
Ficker,et al. [15]
(1998)
Annegers USA retrospective 17 1,535 All ages 7-49
9(7 with
autopsy)
0.35
Nickels,et al. [11]
(2012)
Other USA prospective 7.87 467 <17 <10 1 with autopsy 0.22
Lahtoo,et al. [23]
(1999)
Nashef UK prospective 10 792 All ages 42 1 with autopsy 0.13
Note：a The definition in this row indicates use of the definition of Annegers or the definition of Nashef. Definitions other than these two kinds were regarded as “other”
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Figure 1 Flow chart of the follow-up and determination of the causes of death in the
cohort with epilepsy
